Tumours with high fascin expression could benefit from more aggressive upfront therapy or inclusion in trials evaluating fascin inhibitors (for example, NP-G2-044), or PI3K/Akt pathway inhibitors. This evidence concerns the gene PIK3CA and neoplasm.